Market Size (2019)
2019
$5.76B
Vertical: HealthcareBase Year: 202112 Sections
Market Size (2019)
2019
$5.76B
Projected (2030)
2030
$52.98B
CAGR (2019–2030)
22.3%
22.3%Key Players
109+
Cannabidiol (CBD) is a safe, non-addictive substance found in the cannabis plant. CBD is the second-most abundant cannabinoid found in cannabis after tetrahydrocannabinol (THC). CBD has significant therapeutic benefits such as anti-inflammatory, analgesic, anti-anxiety, and seizure-suppressant properties. According to a survey by the National Center for Biotechnology Information (NCBI) conducted between 2020-2021, about 62% of the population used CBD to treat a medical condition.
The growing research & development and financial support by various private and government organizations for cannabinoid research, rising occurrence of chronic diseases and related complications, and legalization of CBD in various regions are expected to have a positive impact on the global CBD market. However, adverse effects associated with cannabis and stringent government policies are anticipated to restrain the growth of the global CBD market.
The global CBD market was valued at USD 8,430.21 million in 2021, and the market is estimated to grow at USD 52,980.57 million by 2030 and is expected to register a CAGR of 22.79% during the forecast period from 2022 to 2030. In 2021, the North America accounted for the largest market share of 48.51% with a market value of USD 4,089.53 million, followed by Europe with a market value of USD 1,913.84 million in 2021.
The Cannabidiol Market market is projected to grow at a CAGR of 22.3% from 2019 to 2030.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCannabidiol is a safe, non-addictive substance found in the cannabis plant. CBD is the second-most abundant cannabinoid found in cannabis after tetrahydrocannabinol (THC). It has many therapeutic benefits such as anti-inflammatory, analgesic, anti-anxiety, and seizure-suppressant properties. According to a survey by the National Center for Biotechnology Information conducted between 2020–2021, about 62% of the population uses CBD to treat a medical condition. The rising legalization of cannabis-based products and growing R&D in the field is expected to boost the global CBD market growth.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2021
Historical Period
2019 – 2021
Forecast Period
2021 – 2030
Primary Interviews
150+
Historical data (2019–2021) and forecast period (2021–2030)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThreat of New Entrants
The threat of new entrants is medium to high in the global cannabidiol (CBD) market. Any contract development and manufacturing company trying to enter the market is required to accept and abide by the mandatory regulatory standards. However, the budget required for the research & development of a product is low as compared to other industries. The majority of the customers are using products of trusted sellers and are likely to prefer established brands over new market players due to quality concerns, which does not allow new entrants to enter the market easily.
Bargaining Power of Suppliers
Bargaining power of suppliers in the cannabidiol (CBD) market is high. In the global cannabidiol industry, suppliers are raw material manufacturers and intermediate Original Equipment Manufacturers (OEMs). The number of suppliers in the market is limited, which limits the supply of cannabis to product manufacturers for raw material sourcing, thus leaving suppliers with high bargaining power. Switching cost of these suppliers is also medium as the suppliers tend to enter into long-term associations with manufacturers. On the other hand, since expensive materials are used for the manufacturing of CBD products, only a moderate number of viable raw material substitutes are available, which further boosts the bargaining power of suppliers in the market. Other factors, such as the absence of one dominant supplier and availability of marijuana in the black market, increase the bargaining power of suppliers.
Bargaining Power of Buyers
The bargaining power of buyers is medium in the cannabidiol (CBD) market. Patients and hospitals are the primary buyers in this market. This is due to the increasing prevalence of chronic conditions and rising demand for CBD-based products for treatment purposes. In addition, buyers are price-sensitive, which moderately affects their bargaining power in the market. There are a smaller number of manufacturers of CBD-based products in the world, which also affects the bargaining power of buyers. Additionally, switching cost is moderate for buyers as many alternative treatments are available at an effective cost.
Threat of Substitutes
The threat of substitutes in the global cannabidiol (CBD) market is low. In the market, a variety of similar drugs can provide the same medical benefits of cannabinoids. This can be seen in terms of availability of over-the-counter medications such as acetaminophen or ibuprofen or prescription medications such as codeine, can serve as safe, effective alternatives to medical marijuana in the market. But the research evidence suggests that medical cannabis use is associated with decreased opiate medication use because medical cannabis has fewer side-effects compared to other painkillers. Conclusively, it can be said that owing to these factors, the threat of substitute is low in the CBD market.
Intensity of Rivalry
The intensity of rivalry in the global cannabidiol (CBD) market is medium to high. The low degree of product differentiation and a large number of customers increases the intensity of rivalry in the market. As the market is growing at a prominent rate, major players likely have huge opportunities to expand their geographic presence, which is likely to initiate cutthroat competition between competing companies to capture maximum market share in emerging markets. Key market players are trying to develop products in their R&D facility as a part of vertical integration. The companies are engaged in developing processes to lower their manufacturing and logistics cost to increase profitability and to overcome the competition. Moreover, they are also developing advanced products in order to differentiate their brand from that of competitors.
Market estimates by geography (2030)
InsightNorth America leads with $24.23B by 2030, while Europe is projected to grow fastest at a 24.1% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2019 | 2021 | 2030 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $2.83B | $8.81B | $24.23B | 21.6% | 46% |
| Europe | $1.27B | $4.47B | $13.60B | 24.1% | 26% |
| Asia Pacific | $646.16M | $2.14B | $6.18B | 22.8% | 12% |
| Rest of the World | $1.01B | $3.22B | $8.97B | 21.9% | 17% |
| Total | $5.76B | $18.63B | $52.98B | 22.3% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$52.98B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Liquid | $30.06B | 22.3% | 53% |
| Solid | $22.93B | 22.3% | 87% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Cannabidiol Market covering market dynamics, competitive landscape, and strategic outlook.
The Cannabidiol Market market is projected to reach $52.98B by 2030, growing at 22.3% CAGR. The Liquid segment holds the largest share.
The global Cannabidiol (CBD) market is mainly driven by the rising research funding for cannabinoid research, legalization of CBD in various regions, and the rising occurrence of chronic diseases and related complications. However, the adverse effects associated with cannabis and stringent government policies may slow the growth of the market.
There are many private and government organizations supporting the research and development for cannabinoids for medical purposes. Cannabis has numerous medicinal properties by which it can cure various diseases. According to the National Institute of Drug Abuse, in 2020, the National Institute of Health (NIH) supported 330 projects and spent USD 140 million on cannabinoid research and development. During this investment, USD 36 million was spent on 70 projects to examine the therapeutic properties of cannabis, and USD 15 million was spent on 26 projects centered on cannabinoid (CBD). Even in 2019, NIH spent USD 21 million studying therapeutic properties of cannabinoids.
Additionally, Singapore, known for the world's most stringent drug laws, is also funding research projects on medical treatments containing synthetically derived compounds of the cannabis plant. In 2019, the government-run National Research Foundation launched a program to research the therapeutic potential of cannabinoids.
Cannabis and its derivative products are illegal in several Asian and the Middle Eastern countries, but the legal landscape is shifting in several countries. Despite the legal and cultural complications, some countries in Asia are potential markets for CBD products. For instance, in February 2021, the Public Health Ministry of Thailand legalized cannabis for medical use. The use of cannabis is illegal in Japan also, but research into cannabinoids is being undertaken with about 40 farmers given licenses to grow a low-THC strain of Cannabis called Tochigi Shiro. Moreover, In April 2019, Israel legalized exporting marijuana for medical use in Israel. Furthermore, in November 2020, Israel announced that it was moving forward with a plan to legalize recreational cannabis nationally. This is anticipated to transform the Middle Eastern market for the CBD. The status has been improving for the African countries as well. For instance, in March 2021, the Moroccan government approved a bill authorizing the medical, cosmetic and industrial use of cannabis. Likewise, other countries that have legalized the commercial use and export of cannabis in Africa are Lesotho, Zambia and Zimbabwe.
Apart from the well proven medical advantages of cannabis, they also have harmful effects on health. Several studies have been published in the journals finding that heavy or long-term use of cannabis has led to addiction, altered brain development, diminished life satisfaction, cognitive impairment, and poor educational outcomes. It is also found that effects were more adverse in individuals who begin using cannabis-based products as adolescents. The current study has also reported that the most commonly reported non-serious adverse events were dizziness, with an occurrence rate of 15.5% among people exposed to cannabinoids. Long-term use of cannabis is also associated with an increased risk of chronic psychosis-related health disorders and chronic bronchitis. From all the information, it can be concluded that the adverse effects associated with cannabis can strongly impact the growth of the market.
Impact on Gdp Growth
The rising prevalence of COVID-19 is projected to influence market growth over the forecast period. As the coronavirus outbreak continues, the majority of pharmaceutical companies experienced a significant loss, thereby hampering the CBD market. As a result of the COVID-19 crisis and the subsequent global disruptions to supply and demand, world GDP fell sharply during 2020. According to the World Bank, there was a 4.3% decrease in global GDP in 2020. Moreover, every region was subjected to considerable growth downgrades; the US by 3.6%, Euro region by 3.6%, the Middle East & North Africa by 5.0%, Europe & Central Asia by 2.9%, South Asia will contract by 6.7%, and Latin America and the Caribbean by 6.9%. However, East Asia & the Pacific region was estimated to grow by 0.9%. The COVID-19 has adversely affected the manufacturing, supply chain, and distribution channel due to the decreased demand and supply, delay, and unavailability of laborers. These downturns are expected to reverse back in due course of time.
Impact on Consumer Behaviour
Since the COVID-19 has spread across the globe, the consumption pattern of the customers in all industries has been changed significantly. It has been found that the majority of customers in America and Europe have increased their purchase of CBD products in recent months. Due to COVID-19, people focus on staying healthy and boosting immune systems, which encourages consumers to consume different health-focused products, including CBD.
The healthcare industry has adapted to COVID-19 by progressing out on telemedicine and other online consultation services to develop patient access. Due to the COVID-19 pandemic, there are changes in buying behavior of customers. The convenience of buying through an online portal has led to people preferring buying CBD products online. According to a 2019 Consumer Reports study, it was found that around 40% bought their CBD products dispensary, 34% purchase CBD from a retail store, 27% purchase CBD from an online retailer, and 12% purchase CBD from another source. The impact of the pandemic is anticipated to bring significant changes in the market scenario. As a result of this, the trend for purchasing CBD products has favored online distribution. Few companies have grabbed the opportunity and have strengthened their online distribution channel to compensate for the fall in sales through retail stores.
Impact on Region
The global CBD market is majorly categorized into the North America, Europe, Asia-Pacific, and Rest of the World. The North America is the largest market for cannabidiol products due to the increasing use of cannabidiol for medicinal, nonmedicinal, and food ingredients. According to a survey, consumers who have used CBD products in the recent 12 months show about 50% have stocked up or plan to stock up on cannabidiol products. Moreover, according to Alphargreen Group Limited (UK), one of the leaders for certified CBD products, stated that more than 8 million Britons were keen on purchasing CBD products. According to the same study, it was estimated that more than USD 180 million were spent on the same products in the first four months of 2020. With this pace, the CBD products market in the UK reached USD 550 million at a growth rate of 50% by the end of 2020 than 2019. The popularity of CBD is on the rise along with various other products, including hand sanitizers, creams, lotions, and balms. The demand for CBD products is expected to increase in the coming days as many individuals believe buying natural and organic products that will improve immunity.
However, significant regulatory steps are being taken to control the illegal marketing of CBD products during the pandemic. For instance, on April 23, 2020, the US FDA issued a warning letter to companies such as Homeoro Corp DBA Natures CBD Oil Distributions (US), and Biota Biosciences, LLC (US) for illegally marketing CBD products to treat opioid addiction and other serious medical conditions such as Alzheimer's disease, AIDS, and cancer. In addition, they also issued warning letters to CBD online Store and Nova Botanix for illegally marketing CBD products to treat COVID-19.
Europe is the second-largest and fastest-growing cannabidiol (CBD) market due to the rising awareness about clinical applications of cannabis. CBD is legal in many European countries, but there are certain restrictions associated with its use. In Europe, cannabis laws vary from country to country. In the UK, the Food Standards Agency (FSA) has set a deadline for CBD companies to provide more information about their products and their components by March 31, 2021, and submit valid novel food authorization applications. It was also reported that only products with valid applications would be permitted to remain in the market. Irrespective of the pandemic, the government is supporting the market growth by approving import-export across the countries and providing favorable conditions for the market. For instance, in March 2020, Medical Marijuana, Inc. (US) announced that its subsidiary, Kannaway, received approval to import CBD products legally in Russia. Furthermore, the Asia-Pacific holds the third-largest position in the CBD market. In Asia-Pacific countries, cannabis-based products are restricted in the majority of countries. However, due to the increasing cases of epilepsy, cannabis-based products are prescribed by some physicians.
Impact On Pricing
Pricing is one of the important factors for any product to withstand in the market. Due to the COVID-19 pandemic, different industries are impacted to some extent with respect to demand, import & export, and pricing. Hemp biomass had witnessed a decrease in the previous summer, but the pricing had stabilized in 2020. More than a 5% drop in pricing was witnessed for refined extracted products, whereas hempseed and fiber prices have stabilized this year and observed a very little price movement.
The pandemic has changed the business environment for numerous organizations across the globe. The supply chain is the key to fulfill customer demands. Several countries have implemented certain restrictions on imports and exports because of the pandemic. This has also affected the CBD industry as many countries are dependent on other countries for raw material supply, component supply, system supply, and technology. The lockdown and restrictions due to COVID-19 globally have imposed a significant impact on the supply chain, which led to a fluctuation in the prices of CBD products.
Impact On Industry
Unlike other farming industries, cannabidiol (CBD) production has not dropped due to COVID-19, despite all the retail markets have been shut due to lockdown. There are complications in distributing these products through retail stores. This resulted in the shift for CBD demand from retail to online. The demand for online CBD products is increasing rapidly. For example, a CBD brand Gnome Serum, a US-based company, had seen an increase in online sales of about 175% from February to March 2020. Moreover, Exactus Inc. (US) also witnessed an increase in 12% online sales during the lockdown. Moreover, the average order size has also increased nearly threefold. This increase in sales was majorly driven, as the warning of COVID-19 started to become more evident to the public. Consumers started ordering multiple products in much greater quantities due to panic.
COVID-19 has disrupted the supply chain of various industries, including CBD retail distribution. It is evident that the companies that were not able to switch from retail to online faced negative impacts of the pandemic. On the other hand, various US states had taken proper measures to reopen dispensaries to serve the patients. It is expected that the states could impose emergency regulations and allow home delivery of medical products where they are currently not allowed. Moreover, various states like Maryland, Michigan, and Illinois have allowed curbside pickup, while Massachusetts has extended delivery areas for approved dispensaries and allowed patients to purchase two-week supplies at once. Steadily, retail markets will reopen and ease the distribution of CBD products through retail which will further drive the growth of the CBD market.
Profiles of 109 companies operating in the Cannabidiol Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Freedom Leaf Inc
Company Headquarters: Nevada, US Founded: 2013 Workforce: ~ 25 Company Working: Freedom Leaf Inc. is a research-oriented company that focuses on manufacturing and marketing plant-based cannabidiol ingredients. The company has certified cultivation and manufacturing facilities. It has a strong presence in the American region and focuses on strategic collaborations and agreements to improve its business. The Company has also divested non-core Freedom Leaf assets, such as Tierra Life Sciences, Cicero, Las Vegas Extraction, and the Spain Greenhouse, and is in the process of divesting from Accuvape, Freedom Leaf Magazine and La Marihuana in order to optimize its portfolio and future performance. It provides its products under brands such as IrieCBD, Hempology, and Freedom Leaf Leafceuticals
CBD Health Solutions
Company Headquarters: Missouri, US Founded: 2015 Workforce: ~50 Company Working: CBD Health Solutions is involved in the manufacturing, selling, and marketing of hemp-based products in the US. The company operates through three business segments: CBD health solution oils, CBD health solution capsules, and CBD health solution topicals. The company is involved in the manufacturing of cannabidiol oil e-juices, tinctures, and salves. It operates as a subsidiary of Endexx Corporation and provides products to the US-based customers.
Green Roads
Company Headquarters: Florida, US Founded: 2012 Workforce: ~100 Company Working: Green Roads. manufactures and markets CBD products that are used for the treatment of pain, migraines, psoriasis, sleep, and spa therapies. The company is also involved in the development of alternative therapies using Cannabidiol ingredients. In addition, in 2021 Green Roads was ranked as the largest privately-owned CBD company in the US by Brightfield Research Group. Green Roads has received numerous honors for its high-quality products and industry expertise. Moreover, it has a strong distribution network, and it provides its products to more than 10,000 stores throughout the US and other countries.
Folium Biosciences
Company Headquarters: Colorado, US Founded: 2014 Workforce: ~200 Company Working: Folium Biosciences is involved in the cultivation, manufacturing, and marketing of hemp-based ingredients and products. The company is one of the major suppliers of cannabinoid products in the business to business (B2B) segment. The company operates through two business segments, including bulk product and white label products. Under white label products, it offers products related to human wellness, active lifestyle, animal health, and cosmeceuticals. In addition, Folium Biosciences was the first hemp company to be issued a certificate of free sale and a manufactured food establishment license by the Colorado Department of Public Health and Environment. The company has a strong presence in the Americas and has a certified manufacturing facility in Colorado.
Aphria Inc
Company Headquarters: Ontario, Canada Founded: 2013 Workforce: ~2,100 Company Working: Aphria Inc. is a Canada-based company that provides safe, clean, and pure pharmaceutical-grade cannabis to its customers. The company runs its business through retail and wholesale channels both domestically and internationally. In addition to operating in more than 10 other countries besides Canada, Aphria is a significant supplier of medical cannabis to Germany. Moreover, the company operates as a subsidiary of Tilray, Inc (US) which was acquired in December 2020. It also focuses on the research and development of innovative products and spends a significant amount of revenue on R&D Furthermore, the company is directly present in more than ten countries and has a strong presence in all the established markets such as North America, Europe, Africa, and Australia
Medical Marijuana Inc
Company Headquarters: California, US Founded: 2009 Workforce: ~50 Company Working: Medical Marijuana Inc. was the world’s first legal supplier of CBD. The company’s focus is on areas such as the development of the international CBD pipeline, the manufacturing of legal cannabis-based consumer products and drugs, and developing new markets for medical cannabis. It offers products such as hemp oils, cannabidiol drops, and tinctures for consumers. It also uses an online portal for the distribution of its products across the world.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Cannabidiol Market